NCT02667886View on ClinicalTrials.gov

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

April 14, 2022

Study Completion Date

April 14, 2022

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

X4P-001

Continuous, oral dosing

DRUG

axitinib

Continuous, oral dosing

Trial Locations (20)

10029

New York

10461

The Bronx

19104

Philadelphia

20057

Washington D.C.

29605

Greenville

32224

Jacksonville

43623

Toledo

46237

Indianapolis

48201

Detroit

52242

Iowa City

55101

Saint Paul

60637

Chicago

63110

St Louis

70121

New Orleans

77030

Houston

85259

Scottsdale

02215

Boston

07601

Hackensack

06351

Gyeyang-gu

03722

Seongdu

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY